JPRN-jRCTs061210089招募中2 期
A Phase II Study to Evaluate the Safety of Biweekly Docetaxel + Nedaplatin Combination Therapy in Previously Treated Patients with FP and Anti-PD-1 Antibodies in patients with Unresectable or Recurrent or metastatic Esophageal Cancer
agano Hiroaki0 个研究点目标入组 18 人开始时间: 2022年3月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients diagnosed with unresectable or recurrent esophageal cancer who are not eligible for curative treatment (surgery, radiotherapy, chemoradiotherapy)and have been previously treated with 5FU +CDDP and PD-1 blocking antibody
- •1) For unresectable esophageal cancer, all of the following i)-iii) are met.
- •i) Distant metastasis other than #102 mid (middle deep cervical lymph node)or #104 (supraclavicular lymph node).
- •Even if the short diameter of the lymph node is less than 10 mm, it is considered a lymph node metastasis if it can be clearly judged as a tumor lesion by FDG-PET, ultrasonography, or clinical course.
- •ii) Tumor depth is cT1-4a.
- •iii) Dysphagia score <- 2 (semi-solid or harder food intake is possible)and the patient can pass a conventional endoscope.
- •2) For recurrent esophageal cancer, both i) and ii) are met.
- •i) Distant metastasis other than #102 mid (middle deep cervical lymph node) or #104 (supraclavicular lymph node). (Only one distant metastasis in either #102 mid or #104 is eligible if it is a recurrence in the radiation field after radical (chemo)radiation therapy.)
- •Even if the short diameter of the lymph node is less than 10 mm, it is considered as lymph node metastasis if it can be clearly judged as tumor lesion by FDG-PET, ultrasonography, or clinical history.
- •ii) Dysphagia score <- 2 (semi-solid or more solid food intake is possible.)
- •Note) Cases in which recurrence is suspected based on elevated tumor markers or clinical symptoms alone are not applicable. If the patient has a history of multiple cancers other than esophageal cancer, confirm that it is a recurrence of esophageal cancer by clinical history or histological diagnosis.
- •2.The primary lesion is located in the cervical esophagus, thoracic esophagus, or esophagogastric junction (UICC-TNM 7th edition).
- •3.Histopathologically diagnosed as either squamous cell carcinoma or adenosquamous cell carcinoma*.
- •*Siewert type I (ineligible for Siewert type II/III (see 3.1.1.)).
- •4.At least one measurable lesion can be identified on imaging studies within 28 days prior to enrollment.
- •5.Patients within 28 days from disease progression
- •6.Performance status (ECOG): 0 to 1.
- •7.Over 20 years old at the time of enrollment.
- •8.Patients who are expected to survive for 3 months from the start date of treatment.
- •9.The following treatment-free periods must have occurred from the end of the previous treatment.
- •Radiation therapy:4weeks
- •Surgical therapy with organ resection:2weeks
- •Chemotherapy:2weeks
- •Immunotherapy:2weeks
- •Other investigational drugs:4weeks
- •10.Patients whose latest blood test results meet all of the following criteria (within 14days prior to enrollment)
- •6.Adequate organ function within 14days prior to enrollment
- •WBC:<=12,000/mm3
- •Neutrophil:>=1,500/mm3
- •Hb:>=9.0 g/dl
- •Plt:>=100,000/mm3
- •T-Bil:<=1.5mg / dl
- •Patients with obstructive jaundice who have undergone decongestive procedure, such as PTCD, are eligible if the procedure was performed within 14 days prior to enrollment and the most recent test within 14 days prior to enrollment confirms that the patient meets the above criteria (T. Bil <-2.0 mg/dl).
- •AST(GOT),ALT(GPT):within 2.5 times the normal upper limits
- •Ccr:<=1.2mg/dl
- •CCr:>=50ml / min (Cockcroft- Gault)
- •CCr should be greater than or equal to 50 mL/min/body as estimated by the Cockcroft-Gault equation. Even if the estimated value is less than 50 mL/min/body, the patient is eligible if the measured value is confirmed to be 50 mL/min/body or more.
- •11.No blood transfu
排除标准
- •1.Patients with a history of taxane use in the previous treatment history. (Preoperative or postoperative adjuvant therapy and radical chemoradiation can be enrolled if 180 days have passed since the last dose.)
- •2.Patients with Grade 2 or higher peripheral neuropathy at the time of obtaining written informed consent
- •3.Patients who have history of severe drug allergy.
- •4.Patients who have active infectious disease.
- •5.Patients with active multiple cancers (Active multiple cancers are defined as concurrent multiple cancers and heterogeneous multiple cancers with a disease-free interval of 5 years or less. However carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma that are considered curable by local treatment are not included in active multiple cancers).
- •6.Patients have symptomatic bone or brain metastases.
- •7.Patients who has severe complication
- •Infectious disease on antibiotics.
- •diabetes mellitus under treatment or poorly controlled by continuous insulin use
- •poorly controlled hypertension
- •myocardial infarction occurring within 6 months
- •unstable angina pectoris
- •liver cirrhosis
- •Interstitial pneumonia or pulmonary fibrosis
- •8.Patients who want to be pregnant and /or pregnant woman
- •9.Patients with psychosis or psychiatric symptoms that make it difficult to participate in clinical research
- •10.Patients who was judged to be unsuitable for this clinical trial
研究者
相似试验
进行中（未招募）
1 期
A Phase 2b Clinical Study to Evaluate the Safety and Efficacy of Topical Administration ofBacteriophage Therapy TP-102 in Patients with Diabetic Foot InfectioCTIS2023-507716-13-00Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A.80
进行中（未招募）
2 期
JCOG0908: Randomized phase II study of biweekly R-CHOP versus biweekly R-CHOP followed by CHASER as induction therapy for high-dose chemotherapy, LEED, and autologous stem-cell transplantation in poor-risk diffuse large B-cell lymphomaDLBCL, including subtypelymphomatoid granulomatosis(G3)primary mediastinal large B cell lymphomaJPRN-jRCTs031180103YAMAMOTO Kazuhito70
招募中
2 期
Study to assess the Safety and Efficacy of Bacteriophage in the treatment of Diabetic foot infection.CTRI/2023/11/059899TechnoPhage
招募中
2 期
A Phase 2 Study of MK-3475A in Japanese Participants with Recurrent or Metastatic (R/M) or Locally Advanced (LA) unresectable Cutaneous Squamous Cell Carcinoma (cSCC)JPRN-jRCT2041230074Koh Yasuhiro19
进行中（未招募）
不适用
A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-650032) versus Pegasys administered with Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) administered with or without Ribavirin plus 2 direct antiviral agents (BMS 790052 and BMS-650032) (Part B) in chronic hepatitis C genotype-1 treatment na?ve subjects + Administrative Letter 01 (version 1.0, dated 10-Jan-11) - The D-LITE Study:Direct Antiviral Agents plus Lambda Interferon Treatment EvaluatioChronic Hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912EUCTR2010-022568-11-ITBristol-Myers Squibb International Corporation200